Vermillion Q2 Revenues Dip 9 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion reported today a 9 percent drop year over year in second-quarter revenues as licensing revenues retreated 62 percent.

For the three months ended June 30, total revenues were $304,000, down from $344,000 a year ago. While product revenues — comprised completely of sales of the company's OVA1 ovarian cancer test — rose more than 300 percent year over year to $191,000 from $45,000, license revenues fell to $113,000 from $299,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.